Original language | English |
---|---|
Pages (from-to) | 321-326 |
Number of pages | 6 |
Journal | Blood Advances |
Volume | 6 |
Issue number | 1 |
DOIs | |
Publication status | Published - 11 Jan 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood Advances, Vol. 6, No. 1, 11.01.2022, p. 321-326.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma
AU - Kuhnl, Andrea
AU - Roddie, Claire
AU - Kirkwood, Amy A.
AU - Menne, Tobias
AU - Cuadrado, Maria
AU - Marzolini, Maria A.V.
AU - Osborne, Wendy
AU - Sanderson, Robin
AU - O’Reilly, Maeve
AU - Townsend, William
AU - Benjamin, Reuben
AU - Potter, Victoria
AU - Patten, Piers E.M.
AU - Yallop, Deborah
AU - Voo, Stefan
AU - Petrides, George S.
AU - Mulholland, Nicola
AU - Kayani, Irfan
N1 - Funding Information: This work receives funding from the National Institute for Health Research University College London Hospital Biomedical Research Centre (W.T.). I.K. acknowledges funding from the University College London Experimental Cancer Medicine Centre for his post. Funding Information: advisory boards and received honoraria from Kite/Gilead, Novartis, and BMS. A.A.K. has received honoraria from Kite/Gilead. R.S. and M.O. have served on advisory boards and received honoraria from Kite/Gilead and Novartis. T.M. has served on advisory boards and received honoraria from Kite/Gilead, Novartis, BMS, Janssen, Roche, Servier, Pfizer, and Amgen. W.O. has received honoraria from Roche, Takeda, Pfizer, Servier, Kite/Gilead, MSD, Novartis, Bei-gene, Astra Zeneca, Syneos, Autolus, Kyowa Kirin, Abbvie, Incyte, and BMS. W.T. has received honoraria and consultancy fees from Celgene BMS, Incyte, and Roche. V.P. has received honoraria from Kite/Gilead. P.E.M.P. has received research funding from Roche, Kite/Gilead, has served on advisory boards for Novartis and Abbvie, has received honoraria from Abbvie, Astra Zeneca, Gilead, Janssen, and Novartis, and has received support for attending meetings from Abbvie and Janssen. D.Y. has served on advisory boards for Gilead
PY - 2022/1/11
Y1 - 2022/1/11
UR - http://www.scopus.com/inward/record.url?scp=85122962821&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021005807
DO - 10.1182/bloodadvances.2021005807
M3 - Letter
C2 - 34700342
AN - SCOPUS:85122962821
SN - 2473-9529
VL - 6
SP - 321
EP - 326
JO - Blood Advances
JF - Blood Advances
IS - 1
ER -